Actively Recruiting
Continued Treatment with Deucravacitinib for Adults with Systemic Lupus Erythematosus or DiscoidSubacute Cutaneous Lupus After Prior Study Completion
Led by Bristol-Myers Squibb · Updated on 2026-09-09
35
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to continue the administration of Deucravacitinib in adults with Systemic Lupus Erythematosus SLE or Discoid andor Subacute Cutaneous Lupus Erythematosus DLESCLE who have already completed previous studies IM011074 or IM011132. The study is a phase 4, non-randomized, open-label trial sponsored by Bristol-Myers Squibb designed to evaluate ongoing treatment in this patient population. Participants will receive the drug BMS-986165 Deucravacitinib at specified doses on specified days as part of a single group study. This continuation protocol allows participants who completed earlier trials to keep receiving the study drug, with treatment continuing for up to two years. The study focuses on the long-term administration and monitoring of Deucravacitinib in these lupus conditions. During the study, participants will be monitored for safety and treatment response, including tracking the number of participants treated with BMS-986165 over the course of up to two years. The trial includes regular assessments as determined by the study protocol and medical judgement. The total duration of participation will depend on individual treatment continuation and study timelines through January 2028.
CONDITIONS
Brief Title
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here